European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridge, UK.
School of Public Health (Shenzhen), Sun Yat-Sen University, Guangzhou, China.
Sci Rep. 2021 Oct 21;11(1):20833. doi: 10.1038/s41598-021-00121-z.
Several single-cell RNA sequencing (scRNA-seq) studies analyzing immune response to COVID-19 infection have been recently published. Most of these studies have small sample sizes, which limits the conclusions that can be made with high confidence. By re-analyzing these data in a standardized manner, we validated 8 of the 20 published results across multiple datasets. In particular, we found a consistent decrease in T-cells with increasing COVID-19 infection severity, upregulation of type I Interferon signal pathways, presence of expanded B-cell clones in COVID-19 patients but no consistent trend in T-cell clonal expansion. Overall, our results show that the conclusions drawn from scRNA-seq data analysis of small cohorts of COVID-19 patients need to be treated with some caution.
最近发表了几项单细胞 RNA 测序 (scRNA-seq) 研究,分析了对 COVID-19 感染的免疫反应。这些研究大多样本量较小,这限制了可以高度置信地得出的结论。通过以标准化的方式重新分析这些数据,我们在多个数据集上验证了 20 个已发表结果中的 8 个。特别是,我们发现随着 COVID-19 感染严重程度的增加,T 细胞数量持续减少,I 型干扰素信号通路上调,COVID-19 患者中存在扩增的 B 细胞克隆,但 T 细胞克隆扩增没有一致的趋势。总的来说,我们的研究结果表明,需要谨慎对待从 COVID-19 患者小队列的 scRNA-seq 数据分析中得出的结论。